Prolevi Bio on the financing round and focus for 2023
Privately held Prolevi Bio aims improve treatment for many patients suffering from hypoterosis. The company has developed a method that is to improve the drug release in the body and thus relieve symptoms. Preparations are underway for a phase I study that is expected to start in 2023. To take the next step in the development, Prolevi Bio is carrying out a financing round of approximately 3 million euros. CEO Sahil Gupta visited BioStock’s studio to tell us more.
Watch the interview with Prolevi Bio’s CEO Sahil Gupta below.
